These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2625603)

  • 21. Aldosterone response to metoclopramide in patients with prolactinoma: effect of short-term bromocriptine treatment.
    Zacharieva S; Stoeva I; Andreeva M; Kalinov K; Matrozov P; Andonova K
    Methods Find Exp Clin Pharmacol; 1996 Nov; 18(9):593-7. PubMed ID: 9010834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Prolactin-secreting macroadenoma in an adolescent girl: response to the medical treatment and follow-up method].
    de Kerdanet M; Lebrethon MC; Lecornu M
    Pediatrie; 1993; 48(3):233-6. PubMed ID: 8393981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Normal growth and pubertal development during bromocriptine therapy in two patients with prolactinoma.
    Kamel N; Uysal AR; Cesur V; Erdoğan G; Başkal N
    Endocr J; 1995 Aug; 42(4):581-6. PubMed ID: 8556068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Shrinkage of pituitary PRL-secernent adenoma after short-term treatment with bromocriptine long-acting repeatable injections.
    Paoletti AM; Cagnacci A; Mais V; Ajossa S; Guerriero S; Murgia C; Depau GF; Serra GG; Melis GB
    Clin Exp Obstet Gynecol; 1994; 21(2):124-8. PubMed ID: 8070116
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Giant prolactinomas: clinical management and long-term follow up.
    Shrivastava RK; Arginteanu MS; King WA; Post KD
    J Neurosurg; 2002 Aug; 97(2):299-306. PubMed ID: 12186457
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination Treatment with Bromocriptine and Metformin in Patients with Bromocriptine-Resistant Prolactinomas: Pilot Study.
    Liu X; Liu Y; Gao J; Feng M; Bao X; Deng K; Yao Y; Wang R
    World Neurosurg; 2018 Jul; 115():94-98. PubMed ID: 29530699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Giant macroprolactinoma and pregnancy.
    Saraiva J; Gomes L; Paiva S; Ruas L; Carvalheiro M
    Arq Bras Endocrinol Metabol; 2013 Oct; 57(7):558-61. PubMed ID: 24232822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long term therapy of patients with macroprolactinoma using repeatable injectable bromocriptine.
    Ciccarelli E; Miola C; Grottoli S; Avataneo T; Lancranjan I; Camanni F
    J Clin Endocrinol Metab; 1993 Feb; 76(2):484-8. PubMed ID: 8432794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E; Camanni F
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful treatment of a prolactin-producing pituitary macroadenoma with intravaginal bromocriptine mesylate: a novel approach to intolerance of oral therapy.
    Katz E; Schran HF; Adashi EY
    Obstet Gynecol; 1989 Mar; 73(3 Pt 2):517-20. PubMed ID: 2915884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surgical indication after bromocriptine therapy on giant prolactinomas: effects and limitations of the medical treatment.
    Saeki N; Nakamura M; Sunami K; Yamaura A
    Endocr J; 1998 Aug; 45(4):529-37. PubMed ID: 9881903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal.
    Passos VQ; Souza JJ; Musolino NR; Bronstein MD
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3578-82. PubMed ID: 12161478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Remarkable remission of an invasive giant prolactinoma under high-dose bromocriptine monotherapy.
    Szczepanek-Parulska E; Filipowicz D; Kuśmierek A; Stajgis M; Mohol J; Ruchała M
    Pol Arch Intern Med; 2017 Aug; 127(7-8):559-560. PubMed ID: 28817546
    [No Abstract]   [Full Text] [Related]  

  • 34. [Decreased tumor size in hypophyseal macroadenoma--empty sella syndrome].
    Tammann T
    Praxis (Bern 1994); 2001 Feb; 90(7):267-8. PubMed ID: 11256227
    [No Abstract]   [Full Text] [Related]  

  • 35. [Prolactinoma in man: clinical and histological characteristics].
    Trouillas J; Delgrange E; Jouanneau E; Maiter D; Guigard MP; Donckier J; Perrin G; Jan M; Tourniaire J
    Ann Endocrinol (Paris); 2000 Sep; 61(3):253-7. PubMed ID: 10970951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bromocriptine for prolactinoma-related dissociative disorder and depression.
    Cohen AJ
    J Clin Psychopharmacol; 1995 Apr; 15(2):144-5. PubMed ID: 7782492
    [No Abstract]   [Full Text] [Related]  

  • 37. Bromocriptine as a Potential Glucose-lowering Agent for the Treatment of Prolactinoma with Type 2 Diabetes.
    Oshige T; Nakamura Y; Sasaki Y; Kawano S; Ohki T; Tsuruta M; Tokubuchi I; Nakayama H; Yamada K; Ashida K; Tajiri Y; Nomura M
    Intern Med; 2019 Nov; 58(21):3125-3128. PubMed ID: 31243214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NK activity in patients with pathological hyperprolactinemia: effect of bromocriptine.
    Honorati MC; Travaglini P; De Bernardi B; Scorza R; Hu C; Togni ME; Radelli L; Vanoli M; Zanussi C
    Int J Neurosci; 1990 Apr; 51(3-4):303-5. PubMed ID: 2279890
    [No Abstract]   [Full Text] [Related]  

  • 39. Prolactinoma presenting as painful postganglionic Horner syndrome.
    Talkad AV; Kattah JC; Xu MY; Orth EH; Chang JY
    Neurology; 2004 Apr; 62(8):1440-1. PubMed ID: 15111696
    [No Abstract]   [Full Text] [Related]  

  • 40. Prolactinoma.
    Serri O; Beauregard H; Somma M
    Curr Ther Endocrinol Metab; 1994; 5():41-3. PubMed ID: 7704764
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.